News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
TenX Biopharma Licenses Zanolimumab From Genmab A/S
February 5, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PHILADELPHIA, Feb. 4 /PRNewswire/ -- TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S (OMX: GEN).
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
·
1 min read
·
Heather McKenzie
Opinion
Biopharma Must Cope With The Fetal Bovine Serum Squeeze
February 17, 2026
·
5 min read
·
Tom Kutrubes
Manufacturing
Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand
February 17, 2026
·
4 min read
·
Nick Paul Taylor
Opinion
2026 Could Mark a Turning Point for American Innovation
February 16, 2026
·
4 min read
·
John Stanford
